Response
Drs. Trichopoulou and Lagiou make a valid and interesting point. Our focus on secular changes in total fat consumption as a possible cause of the recently observed decrease in U.S. cancer mortality rates actually refers to a population (North America) in which olive oil plays a relatively minor role in the diet. Clearly, a unique feature of the Mediterranean diet is its reliance on olive oil, and there is mounting epidemiologic and experimental evidence that olive oil may provide some reduction in the risk of a variety of chronic diseases including heart disease, cancer, diabetes, and perhaps osteoporosis. It should be noted, however, that there are other components of the Mediterranean diet that may also confer protection, such as high consumption of tomatoes, grains, nuts, fruit, and yogurt, as well as a lower consumption of animal fats and vegetable oils, rendering it difficult to single out the effects of olive oil per se. Nonetheless, Drs. Trichopoulou and Lagiou are correct in pointing out that our emphasis on secular changes in total fat consumption as the possible cause of the recent drop in U.S. cancer mortality rates may not be generalizable to other countries, particularly those such as Greece and Spain in which olive oil plays a central role in the diet.
Re: Relationship Between Lifetime Ovulatory Cycles and Overexpression of Mutant p53 in Epithelial Ovarian Cancer
Schildkraut et al.
(1) recently reported an association between number of lifetime ovulatory cycles and the risk of p53-overexpressed invasive epithelial ovarian cancer, but not of p53-negative cancer. From the data they presented, I conclude exactly the opposite: p53-positive and p53-negative cancers are equally associated with ovulationrelated risk factors, the sole exception being age at diagnosis, which was on average some 3 years greater for the p53-positive case subjects. The study participants were all less than 55 years of age at diagnosis/interview; the majority were premenopausal or perimenopausal. Schildkraut et al. estimated the number of lifetime ovulatory cycles from a linear combination of five factors: age at most recent menstrual period (''index age''), age at menarche, and total durations of pregnancies, breastfeeding, and oral contraceptive use. None of the last four mentioned factors differed significantly between the p53-positive and p53-negative case subjects [P ‫ס‬ .71, .14, .06, and 0.23, respectively (1) ]. Comparing p53-positive and p53-negative cancers, the decreasing odds ratio trends with increasing months pregnant were very close (1), consistent in magnitude with the protective trends seen for parity in many other studies (2,3). Similarly, p53-positive and p53-negative cancers had virtually identical odds ratio trends with duration of oral contraceptive use (1), again of the same magnitude as seen elsewhere (2,3). Age at menarche and duration of breastfeeding contributed very little to the variation in number of ovulatory cycles (1). Thus, only index age is responsible for the purported difference in risk according to lifetime ovulatory cycles.
Furthermore, the authors' adjustment for continuous age terms need not remove the age effect present in the categories of lifetime ovulatory cycles. It is straightforward to show that, even with adjustment for age as a continuous term, age at diagnosis can completely account for the pattern of odds ratios in lifetime ovulatory cycles seen by Schildkraut et al.
While the suggested biologic rationale-that p53 overexpression indicates ovulatory proliferation-induced, preneoplastic DNA damage (4)-is attractive, the data of Schildkraut et al. provide evidence to the contrary, that p53 overexpression more likely results from damage occurring during neoplastic proliferation of the tumors. They show that, in addition to older age at diagnosis, p53-positive tumors are more likely to be of poorer differentiation than p53-negative tumors (P<10 −5 ) and of distant rather than local-regional stage at diagnosis (P ‫ס‬ .0002) (1). These wellknown features (4-6) thus indicate that p53-positive cancers are those diagnosed later in the neoplastic process, when more genetic errors have accumulated. Therefore, the results do not provide evidence for p53-specific causal mechanisms in the pathogenesis of ovarian cancer.
Finally, Schildkraut et al.
(1) state that pregnancy, oral contraceptive use, and lactation all convey their protective effects only through anovulation. However, the number of analyzed case subjects (n ‫ס‬ 197) provided insufficient study power to make this conclusion. Ovulation may be involved in the disease process, but it cannot be the entire mechanism (7). Simply put, the reduction in risk with parity [odds ratio ‫ס‬ 0.83 for each successive pregnancy (2) 
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In our recent article (1), we concluded that exposure to a high number of ovulatory cycles was associated with an increased risk of developing ovarian cancers that overexpress p53. Although the data that we presented were adjusted for various potential confounders, including age, Dr. Risch suggests that all the variation in ovulatory exposure may be explained by age. Dr. Risch also suggests that the relationship between age and p53-positive ovarian cancer is explained by the association between late stage ovarian cancer and p53 overexpression and is a result of tumor progression.
Because of the issues raised by Dr. Risch, we conducted a paired-matched, case-control analysis applying a conditional logistic regression model. Control subjects were matched to the p53-positive ovarian cancer patients on the basis of ''exact'' age and Surveillance, Epidemiology, and End Results (SEER) registry 1 in a ratio of 4:1 to achieve a sufficient statistical power. Because of the excess number of available control subjects, we were able to achieve exact age matches for all 105 p53-positive ovarian cancer patients. Odds ratios for medium (versus low) ovulatory cycle exposure and high (versus low) ovulatory cycle exposure were 4.9 (95% confidence interval [CI] ‫ס‬ 1.4-17.6) and 15.8 (95% CI ‫ס‬ 3.8-66.0), respectively. Thus, these results, matched by age and controlling for menopausal status and nulliparity, are consistent with those of our original article and strengthen our conclusion concerning the relationship between ovulatory cycle exposure and ovarian cancer.
We also compared the p53-positive ovarian cancer patients with control subjects, according to stage, and found a relationship between ovulation and casecontrol status, regardless of stage. For women diagnosed with local or regional disease, controlling for age, menopausal status, and nulliparity, adjusted odds ratios for medium (versus low) and high (versus low) ovulatory cycle exposure were 3.2 (95% CI ‫ס‬ 0.4-27.2) and 6.5 (95% CI ‫ס‬ 0.6-71.0), respectively. For women with advanced disease, adjusted odds ratios were 6.7 (95% CI ‫ס‬ 1.1-42.2) and 13.8 (95% CI ‫ס‬ 2.0-95.5) for medium (versus low) and high (versus low) ovulatory exposure, respectively. Another plausible interpretation of the association between p53 mutations and advanced stage is that ovarian cancers have a more aggressive behavior because of their p53 status and are therefore more likely to be detected at an advanced stage. However, the biologic basis for the association between p53 and advanced stage ovarian cancer has not been established, and caution must be taken when interpreting this relationship, since precursor lesions for ovarian cancer remain undefined.
Although these additional analyses strengthen our original conclusion concerning ovulation and the risk of developing ovarian cancer, a larger study that is also representative of older, postmenopausal women with ovarian cancer is needed to confirm our current findings and to achieve a better understanding of the pathogenic processes leading to this disease. Re: Carcinogenicity of the Drinking Water Mutagen 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone in the Rat Komulainen et al. (1) recently reported dose-dependent tumor incidence in seven distinct tissues of male and female Wistar rats that had consumed drinking water containing 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX). They suggested cautiously that MX should be studied as a candidate risk factor to explain a ''possible association between consumption of chlorinated drinking water and cancer in humans,'' but they noted specifically that their findings ''cannot be extrapolated to humans.'' However, in their accompanying editorial, Melnick et al. (2) proceeded with just such an extrapolation. They estimated potential cancer risks to humans from MX in drinking water and compared these risks with those from two other disinfec-
